Intravitreal Bevacizumab for the Treatment of Central Serous Chorioretinopathy.
The benefit of intravitreal bevacizumab injection in the long-standing idiopathic central serous chorioretinopathy is described. Intravitreal injection of 1.25 mg of bevacizumab was given to a patient, who complained of reduced vision for 10 months due to idiopathic central serous chorioretinopathy. Within a week, his visual acuity improved from 20/80 to 20/25; 3 months later, the visual acuity reached 20/20 with complete resolution of the serous retinal detachment, as was demonstrated by optical coherence tomography. No recurrences or complications were found for a period of 6 months.
Alomran
Mohamed Shaker
MS